EYPT EyePoint Pharmaceuticals
- 17.910
- +0.310+1.76%
EyePoint Pharmaceuticals News
Daily ticket tracking | Tesla earns 48x in a single call! The bullish ratio has been rising for four consecutive days
Apple's premium for multiple calls due on Friday doubled; Amazon's previous sales of multiple call orders were stolen. Among them, the volume of calls due on Friday and with an exercise price of 190/200 US dollars all exceeded 20,000.
Bullish Buy Rating Reaffirmed for EyePoint Pharmaceuticals With a $39 Price Target
Over $10M Bet On This Healthcare Stock? Check Out These 4 Stocks Insiders Are Buying
Although U.S. stocks closed higher on Monday, there were a few notable insider trades.When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stoc
EyePoint Pharmaceuticals(EYPT.US) 10% Shareholder Buys US$10.49 Million in Common Stock
$EyePoint Pharmaceuticals(EYPT.US)$ 10% Shareholder Cormorant Asset Management, LP purchased 581.77K shares of common stock on Apr 18, 2024 at an average price of $18.03 for a total value of $10.49 mi
Insider Sellers Might Regret Selling EyePoint Pharmaceuticals Shares at a Lower Price Than Current Market Value
EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) stock price has dropped 17% in the previous week, but insiders who sold US$1.3m in stock over the past year have had less luck. Given that the average s
Baird Sees Weakness in Ocular Shares "Overdone" in Wake of Phase 1 Data
Buy Recommendation: EyePoint Pharmaceuticals' Promising Outlook With EYP-1901 for Diabetic Retinopathy and AMD
Daily rights tracking | Trump's media rose 40% in two days! Earn eight times the option premium with a single call
Tesla's multiple single options due today doubled and surged; TSMC options trading volume surged by nearly 60%, slightly rising to 68% from a bullish ratio.
Veru, EyePoint Pharmaceuticals, SINTX Technologies Among Healthcare Movers
Daily Futures Tracking | The bearish ratio has been rising for two days in a row! Tesla's two-card push doubles and soars
AMD's bullish ratio rose to 63% for two consecutive days. Calls due on Friday and with an exercise price of $165/170 were active, at 68,000 and 41,000, respectively.
Strong Buy Rating for EyePoint Pharmaceuticals Amid Promising Developments in Ophthalmic Therapies
Tim Chiang, an analyst from Capital One Financial, maintained the Buy rating on EyePoint Pharmaceuticals (EYPT – Research Report). The associated price target remains the same with $50.00.
Recent EyePoint Weakness Seen As Buying Opportunity -- Market Talk
0756 ET - A recent sell-off in shares of EyePoint Pharmaceuticals is an opportunity to buy, according to Mizuho. In a research note, analyst Graig Suvannavejh says a more than 30% drop in EyePoint sha
Revenue Downgrade: Here's What Analysts Forecast For EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)
Market forces rained on the parade of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) shareholders today, when the analysts downgraded their forecasts for this year.
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Analysts Just Slashed This Year's Revenue Estimates By 22%
Critical Insights From EyePoint Pharmaceuticals Analyst Ratings: What You Need To Know
5 analysts have expressed a variety of opinions on EyePoint Pharmaceuticals (NASDAQ:EYPT) over the past quarter, offering a diverse set of opinions from bullish to bearish.In the table below, you'll f
HC Wainwright & Co. Maintains Buy on EyePoint Pharmaceuticals, Maintains $33 Price Target
HC Wainwright & Co. analyst Yi Chen maintains EyePoint Pharmaceuticals (NASDAQ:EYPT) with a Buy and maintains $33 price target.
EyePoint Pharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/08/2024 33.23% HC Wainwright & Co. $33 → $33 Maintains Buy 02/16/2024 57.45% Mizuho $30 → $39 Maintains
Analysts Are Bullish on Top Healthcare Stocks: Oxford BioMedica (OXBDF), EyePoint Pharmaceuticals (EYPT)
EyePoint Pharmaceuticals Inc (EYPT) Reports Growth Amidst Strategic Shifts in Q4 and Full-Year 2023
Earnings Call Summary | EyePoint Pharmaceuticals(EYPT.US) Q4 2023 Earnings Conference
The following is a summary of the EyePoint Pharmaceuticals, Inc. (EYPT) Q4 2023 Earnings Conference Call Transcript:Financial Performance:EyePoint Pharmaceuticals reported total net revenue of $14 mil
Analysis
Price Target
No Data
